There are currently 44 clinical trials in Irving, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University Hills Clinical Research, Pfizer Investigational Site, Novo Nordisk Investigational Site and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551
Recruiting
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.
Gender:
All
Ages:
Between 18 years and 125 years
Trial Updated:
02/28/2024
Locations: NEXT Dallas, Irving, Texas
Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC
NCT06162221
Recruiting
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other. The first two subprotocols include the following: Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: NEXT Oncology Dallas, Irving, Texas
Conditions: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Register for Updates
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144
Recruiting
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: NEXT Oncology Dallas, Irving, Texas
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer
Register for Updates
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
NCT06042855
Recruiting
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. Participants will self-report any new or worsening symptoms or medical events experienced while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a partic... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
02/12/2024
Locations: Texas Health Physicians Group, Irving, Texas
Conditions: Covid19
Register for Updates
DIALYSIS-TIR Study
NCT06042153
Recruiting
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 d... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/11/2024
Locations: DaVita UT Southwestern - Irving, Irving, Texas
Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Register for Updates
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
NCT03104517
Recruiting
This study evaluates the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR; generic name: iltamiocel) compared to a placebo in the reduction of stress incontinence episode frequency in adult female patients with post-surgical persistent or recurrent stress urinary incontinence (SUI). Half of the participants will receive AMDC-USR (injections with cells) and the other half will receive placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: Cedar Health Research, Irving, Texas
Conditions: Stress Urinary Incontinence
Register for Updates
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
NCT05821777
Recruiting
The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: NEXT Oncology - Dallas, Irving, Texas
Conditions: Advanced Solid Tumor
Register for Updates
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
NCT05399654
Recruiting
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: NEXT Oncology, Irving, Texas
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.
NCT05831995
Recruiting
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/08/2024
Locations: Next Oncology, Irving, Texas
Conditions: Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
Register for Updates
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors
NCT05935098
Recruiting
This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/03/2024
Locations: Next Dallas, Irving, Texas
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
Register for Updates
CLN-418 Study on Subjects With Advanced Solid Tumors
NCT05306444
Recruiting
Study to evaluate the safety and tolerability of the study drug CLN-418, to determine the maximum tolerated dose and/or recommended Phase 2 study dose of CLN-418.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: NEXT Oncology, Irving, Texas
Conditions: Advanced Solid Tumor
Register for Updates
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: NEXT Dallas, Irving, Texas
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Platinum-resistant Ovarian Cancer, Cutaneous Squamous Cell Carcinoma
Register for Updates